FacebookTwitterGoogle+RedditEmail

Born With a Statin Deficiency?

by MARTHA ROSENBERG

When Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, MA presented the results of the AstraZeneca-funded JUPITER study at the American Heart Association conference in November–JUPITER standing for The Justification for the Use of Statins in Primary Prevention–there were a lot more stenographers than skeptics in the press corps.

How could a drug company-funded study designed to show why the general population should use its drug (Crestor, or rosuvastatin) be objective? Or even newsworthy?

Especially when its lead author is co-inventor on the related patent?

And its authors list 131 financial ties to drug companies? Hello?

But the press didn’t let overt conflicts of interest–COIs as pharma calls them because they’re so common–ruin the story.

“AstraZeneca’s Crestor Cuts Death, Heart Attack,” exalted Reuters remembering the PR dictim of getting Name and Company in the headline. “Crestor Study Seen Changing Preventive Treatment!”

“Wider Cholesterol Drug Use May Save Lives,” trumpeted other headlines.

“Statins For Everyone!”

“Crestor In The Water?”

Was this the same Crestor which was vilified in a Lancet editorial three months after its 2003 US approval as “inadequately investigated”?

Named as one of the top five most dangerous drugs by the FDA’s Dr. David “Vioxx” Graham on Capitol Hill in 2004?

Petitioned for recall by the Washington D.C. based Public Citizen?

Found worthless against chronic heart failure just one month earlier in Lancet?

In the feeder frenzy to cover the self-engineered drug breakthrough, where was press mention of another American Heart Association finding about Crestor in its journal Circulation in 2005? [111:3051-3057]

That Crestor “was significantly more likely to be associated with the composite end point of rhabdomyolysis, proteinuria, nephropathy, or renal failure,” than other drugs?

Where was mention of the FDA warning about rhabdomyolysis–the muscle disease that did Bayer’s Baycol in–that was added to Crestor in 2005 after a patient death–along with warnings to the physician about Crestor use in Asian patients, people with severe kidney disease and patients taking cyclosporine?

Oops.

But while the gee whiz press focused on the JUPITER study’s startling results–the Crestor group had a 54 percent reduction in heart attacks, 48 percent reduction in strokes and 20 percent reduction in death compared to placebo–especially in light of the fact that the study group was free of heart disease and high cholesterol, most doctors wouldn’t drink the AstraZeneca Kool-Aid.

The study’s 17,802 enrollees may have had normal levels of the bad LDL cholesterol but some were “walking vasculopaths,” with abnormal C-reactive protein levels [CRP] which indicate inflammation in the body said Dr. Bernadine Healy, health editor for U.S. News & World Report.

“As a result, the JUPITER trial was riddled with obesity, high blood pressure, prediabetes, and genes predisposing to heart disease,” said Healy. “Almost 3,000 enrollees were smokers, a big time CRP elevator, and only 10 percent took aspirin, an inexpensive preventive medicine that protects against both heart disease and stroke. (Aspirin also lowers CRP.) Other study patients were really healthy, free of any known risk factors and yet had elevated CRP for no obvious reason.”

While the press bought AstraZeneca’s contrivance that the JUPITER study was so conclusive it was ended early, many of the 470 doctors who posted online comments after the study in the New England Journal of Medicine (Nov. 20, 2008) said you ended the trial WHEN?

“It is well established that RCTs [randomized controlled trials] stopped early overestimate benefits significantly,” wrote a physician from Rochester, MN.

“It is shocking that this trial was terminated 50% through, based on a small absolute benefit, with real questions about long term risk,” said a poster from the Public Health Law Program, LSU Law Center.

“There is no justification for stopping the follow-up, even if the triallists felt it was unethical to recruit new patients,” wrote a physician from Yorkshire, UK. “Congratulations to AstraZeneca for selling the results to the uncritical lay media. I feel sorry for all the family doctors who will be pestered by patients for some time to come.”

Doctors also balked at the study’s ipso facto preference for a pill over lifestyle changes like diet and exercise–including the well known Dr. Dean Ornish of Preventive Medicine Research Institute who noted the nation spent $20 billion on cholesterol-lowering drugs last year.

While cardiologists were soft on the study–except one who assailed the Western “pandemic food addiction and the mirage of immortality in a bottle of pills”–many other doctors detected disease mongering behind JUPITER of the sort that sold HRT and Vioxx to anyone over 50.

Even a medical student wasn’t impressed.

“I don’t think risking the patient’s life by giving him statins is a correct procedure. I would be giving him/her benefits for a disease which has not been diagnosed yet and increasing the odds of developing another disease (Diabetes),” she wrote.

MARTHA ROSENBERG is staff cartoonist on the Evanston Roundtable. She can be reached at mrosenberg@evmark.org

 

 

 

 

 

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:
June 28, 2016
Jonathan Cook
The Neoliberal Prison: Brexit Hysteria and the Liberal Mind
Paul Street
Bernie, Bakken, and Electoral Delusion: Letting Rich Guys Ruin Iowa and the World
Anthony DiMaggio
Fatally Flawed: the Bi-Partisan Travesty of American Health Care Reform
Mike King
The “Free State of Jones” in Trump’s America: Freedom Beyond White Imagination
Antonis Vradis
Stop Shedding Tears for the EU Monster: Brexit, the View From the Peloponnese
Omar Kassem
The End of the Atlantic Project: Slamming the Brakes on the Neoliberal Order
Binoy Kampmark
Brexit and the Neoliberal Revolt Against Jeremy Corbyn
Doug Johnson Hatlem
Alabama Democratic Primary Proves New York Times’ Nate Cohn Wrong about Exit Polling
Ruth Hopkins
Save Bear Butte: Mecca of the Lakota
Celestino Gusmao
Time to End Impunity for Suharto’’s Crimes in Indonesia and Timor-Leste
Thomas Knapp
SCOTUS: Amply Serving Law Enforcement’s Interests versus Society’s
Manuel E. Yepe
Capitalism is the Opposite of Democracy
Winslow Myers
Up Against the Wall
Chris Ernesto
Bernie’s “Political Revolution” = Vote for Clinton and the Neocons
Stephanie Van Hook
The Time for Silence is Over
Ajamu Nangwaya
Toronto’s Bathhouse Raids: Racialized, Queer Solidarity and Police Violence
June 27, 2016
Robin Hahnel
Brexit: Establishment Freak Out
James Bradley
Omar’s Motive
Gregory Wilpert – Michael Hudson
How Western Military Interventions Shaped the Brexit Vote
Leonard Peltier
41 Years Since Jumping Bull (But 500 Years of Trauma)
Rev. William Alberts
Orlando: the Latest Victim of Radicalizing American Imperialism
Patrick Cockburn
Brexiteers Have Much in Common With Arab Spring Protesters
Franklin Lamb
How 100 Syrians, 200 Russians and 11 Dogs Out-Witted ISIS and Saved Palmyra
John Grant
Omar Mateen: The Answers are All Around Us
Dean Baker
In the Wake of Brexit Will the EU Finally Turn Away From Austerity?
Ralph Nader
The IRS and the Self-Minimization of Congressman Jason Chaffetz
Johan Galtung
Goodbye UK, Goodbye Great Britain: What Next?
Martha Pskowski
Detained in Dilley: Deportation and Asylum in Texas
Binoy Kampmark
Headaches of Empire: Brexit’s Effect on the United States
Dave Lindorff
Honest Election System Needed to Defeat Ruling Elite
Louisa Willcox
Delisting Grizzly Bears to Save the Endangered Species Act?
Jason Holland
The Tragedy of Nothing
Jeffrey St. Clair
Revolution Reconsidered: a Fragment (Guest Starring Bernard Sanders in the Role of Robespierre)
Weekend Edition
June 24, 2016
Friday - Sunday
John Pilger
A Blow for Peace and Democracy: Why the British Said No to Europe
Pepe Escobar
Goodbye to All That: Why the UK Left the EU
Michael Hudson
Revolts of the Debtors: From Socrates to Ibn Khaldun
Andrew Levine
Summer Spectaculars: Prelude to a Tea Party?
Kshama Sawant
Beyond Bernie: Still Not With Her
Mike Whitney
¡Basta Ya, Brussels! British Voters Reject EU Corporate Slavestate
Tariq Ali
Panic in the House: Brexit as Revolt Against the Political Establishment
Paul Street
Miranda, Obama, and Hamilton: an Orwellian Ménage à Trois for the Neoliberal Age
Ellen Brown
The War on Weed is Winding Down, But Will Monsanto Emerge the Winner?
Gary Leupp
Why God Created the Two-Party System
Conn Hallinan
Brexit Vote: a Very British Affair (But Spain May Rock the Continent)
Ruth Fowler
England, My England
FacebookTwitterGoogle+RedditEmail